Grail Shares Plunge Following Clinical Trial Setback

Friday witnessed a dramatic sell-off in Grail’s stock, triggered by disappointing news from a major clinical study. While the core objective of the large-scale NHS Galleri trial was not met, a deeper look at the details and the latest financial results reveals a more nuanced picture. The key question for investors is whether the company’s substantial cash reserves can offset the severe loss of market confidence.

Financial Performance Shows Underlying Strength

Amid the clinical news, Grail released its fiscal year 2025 results, which provided some counterbalance to the negative sentiment. The company reported fourth-quarter revenue of $43.6 million, a 14% increase year-over-year. This growth was driven significantly by its U.S. operations, where sales of the Galleri test surged 31% to $41.3 million. For the full year, Grail sold more than 185,000 tests.

On the bottom line, the company performed better than Wall Street had anticipated. The loss per share for the final quarter was $2.44, beating analyst consensus estimates that had projected a loss ranging from $2.70 to $4.01. Management highlighted a robust cash position of $904.4 million at year-end, stating this provides financial security through 2030.

Primary Endpoint Missed in Pivotal Trial

The catalyst for the stock’s decline was the outcome of the NHS Galleri study, which involved 142,000 participants. Grail announced late Thursday that the trial failed to meet its primary endpoint. Researchers were unable to demonstrate a statistically significant reduction in combined stage III and IV cancer diagnoses.

Should investors sell immediately? Or is it worth buying Grail?

Despite this core failure, the company pointed to encouraging data from secondary analyses. In a group of twelve particularly lethal cancers, stage IV diagnoses in later screening rounds decreased by over 20%. Furthermore, the detection rate for the Galleri test was four times higher than that of standard care. The market, however, focused overwhelmingly on the missed primary goal. Shares collapsed from a Thursday closing price of $101.53 to as low as $53 during Friday morning trading.

Analyst Outlook: Downgraded Targets but Maintained Faith

This clinical data emerges at a critical juncture for Grail, which submitted a Pre-Market Approval (PMA) application to the U.S. FDA in January 2026. Regulatory scrutiny is now a focal point, as observers wait to see how the agency will assess the missed primary endpoint from the NHS study. Some market experts suggest U.S. regulators may place greater emphasis on specific U.S. trial data also included in the submission.

Equity researchers swiftly adjusted their models in response. Canaccord Genuity reduced its price target from $105 to $80, while Baird cut its target from $113 to $82. Significantly, both firms maintained their positive ratings on the stock. They characterized the market’s severe reaction as an overreaction, citing the test’s demonstrated success in early detection of deadly cancers and the long-term potential of the underlying technology.